Precisio Biotix Therapeutics (“Precisio”) has announced the acquisition of CC Bio, creator of the ZEUS anti-bacterial lysin platform. This bio-informatics platform is highly complementary to Precisio’s LysiThru™ high-throughput lysin screening system. CC Bio is led by UK-trained PhD scientists Dr. Matthew Cummings and Dr. David Corcoran. Precisio is a clinical-stage biotech company creating lower-cost novel precision engineered biological antibacterials, with an initial focus on skin and lung infections.
Read the full article: Precisio Biotix Therapeutics Acquires London-Headquartered CC Bio //
Source: https://www.prnewswire.com/news-releases/precisio-biotix-therapeutics-acquires-london-headquartered-cc-bio-adding-world-class-antibacterial-platform-and-top-scientists-302077009.html